Epidemiology, prognosis, and clinical manifestation of cardiovascular disease in COVID-19
| Autor: | Ciro Santoro, Vittoria Cuomo, Roberta Esposito, Giovanni Esposito, Mario Enrico Canonico, V Capone, Maria Prastaro, Federica Ilardi |
|---|---|
| Přispěvatelé: | Capone, V., Cuomo, V., Esposito, R., Canonico, M. E., Ilardi, F., Prastaro, M., Esposito, G., Santoro, C. |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Prognosi Pneumonia Viral Comorbidity Disease 030204 cardiovascular system & hematology Disease cluster medicine.disease_cause Betacoronavirus 03 medical and health sciences 0302 clinical medicine myocardial damage cardiovascular disease Epidemiology Pandemic Internal Medicine Humans cardiovascular risk factor Medicine 030212 general & internal medicine Intensive care medicine Pandemics Coronavirus SARS-CoV-2 Coronavirus Infection business.industry Incidence Incidence (epidemiology) COVID-19 General Medicine Prognosis medicine.disease Pneumonia Cardiovascular Diseases Coronavirus Infections Cardiology and Cardiovascular Medicine business Human |
| Zdroj: | Expert Review of Cardiovascular Therapy |
| ISSN: | 1744-8344 1477-9072 |
| Popis: | Introduction: At the end of 2019, a novel coronavirus was identified as the cause of a pneumonia cluster in Wuhan, China. Since then, the contagion has rapidly spread all over the world resulting in a global pandemic. Since frequent cardiovascular (CV) system involvement has soon been detected in patients occurring coronavirus disease 2019 (COVID-19), we would provide a simple review available to cardiologists who are going to be involved in the management of COVID-19 patients from several levels: from diagnosis to prevention and management of CV complications. Areas covered: We investigate the role of CV diseases in COVID-19: from incidence of CV comorbidities to their negative impact on prognosis. We also search Literature in order to identify the main CV manifestations in patients occurring virus infection and their management by cardiologists. Expert opinion: Specific treatments for CV involvement associated with COVID-19 are still debated. Results from ongoing trials are needed to further clarify issues about the therapeutic approach, which is constantly changing according the continuous flow of published evidences. Finally, it seems necessary to sensitize all population to raise awareness on CV diseases in COVID era, to hinder underestimation of both new-onset acute CV diseases and consequences of chronic mistreated CV diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|